Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

">6:00 p.m.)

As part of the multicenter CONCEPT trial, Dr. Goy tested the efficacy and safety of denileukin diftitox, a genetically engineered fusion protein that targets cancers that express the interleukin-2 receptor. The drug was tested head-to-head against the standard "CHOP" (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regimen in a Phase II study in which the patients receiving the new drug were also treated with CHOP. The study group consisted of patients newly diagnosed with aggressive T-cell lymphomas.  Researchers found the combination therapy effective, with a 68% overall response rate and 57% complete response rate.  As a result, they are starting a multicenter comparison study.

About the John Theurer Cancer Center at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group ... is teaming up with the Heartland Blood Center and offering ... drive. The drive takes place Saturday, Jan. 18 at the ... 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... HARBIN, China, April 23 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... CSKI ), a,leading fully integrated pharmaceutical company ... today announced that it,obtained approvals from the State Food ... Geranium ointment and Musk liniment for pain relief. , ...
... China and LOS ANGELES, April 23 /PRNewswire-Asia-FirstCall/ --, - Fourth ... Income was $0.9 Million and Diluted EPS of $.03, ... - 2008 Gross Profit Margin Improved 340 Basis Points to 20.1%, ... EPS of, $0.13, - 2008 ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the ... and internationally, which recently announced it has decreased long-term ... has eliminated another $817,000 of long-term debt. "The remaining ...
Cached Biology Technology:China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 2China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11Cord Blood America Further Reduction, $817,000, in Long-Term Debt 2
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... new study by a University of Exeter researcher has ... of wild camels thriving in Australia,s remote outback have ... scale. , Sarah Crowley, of the Environment and Sustainability ... the history of the camel in Australia, from their ... to their current status as unwelcome "invader." , The ...
(Date:4/23/2014)... many social mammals, ravens form different types of social ... and they also form strict dominance relations. From a ... a key ability in daily social life ("knowing who ... group members have with each other sets the stage ... results of this study have been published in the ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... Coating Stabilizer has been developed ... or immobilized proteins on microwell plates/strips. ... and activity of the antibody or ... immunoassay components. Product is filtered ...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: